Latest News

Olverembatinib has shown promising clinical efficacy in SDH-deficient gastrointestinal stromal tumors, says Haibo Qiu, MD.
Antitumor Activity Seen With Olverembatinib in GIST Subtype

June 8th 2024

Olverembatinib has shown promising clinical efficacy in SDH-deficient gastrointestinal stromal tumors, says Haibo Qiu, MD.

No patients with dMMR rectal cancer enrolled on a phase 2 study required subsequent chemotherapy or radiation following treatment with dostarlimab.
Clinical CRs Seen in Entire Dostarlimab dMMR Rectal Cancer Cohort

June 3rd 2024

The median progression-free survival and overall survival was extended with rivoceranib among those with unresectable HCC in the CARES-310 trial.
Camrelizumab Combo Improves PFS/OS Vs Sorafenib in Advanced HCC

June 2nd 2024

The safety profile of zanidatamab in the HERIZON-BTC-01 trial appears to remain consistent after longer follow-up.
Sustained Responses Achieved With Zanidatamab in HER2+ Biliary Tract Cancer

June 2nd 2024

The FDA has set a new Prescription Drug User Fee Act date of November 9, 2024, for zolbetuximab in this gastric cancer population.
FDA Acknowledges Zolbetuximab BLA Resubmission for CLDN18.2+ Gastric Cancer

May 31st 2024